My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

59.65 +0.39 (+0.66%)

Streaming Delayed Price Updated: 10:10 AM EST, Feb 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 4 5 6 7 8 9

...

38 39 Next >

New Study Shows Shingles Vaccine Linked To 20% Lower Dementia Risk, GSK Stock Pops ↗

April 03, 2025

A study of over 280,000 adults found that the shingles vaccine reduced dementia risk by 20%, with a stronger effect in women.

Via Benzinga

Looking Into GSK's Recent Short Interest ↗

March 26, 2025

Via Benzinga

FDA Approves GSK's Oral Antibiotic For Urinary Tract Infections For Females Aged 12 Years And Older ↗

March 26, 2025

The FDA approved GSK's Blujepa for uncomplicated UTIs in female adults and pediatric patients, with phase 3 trials showing strong efficacy vs. nitrofurantoin.

Via Benzinga

Pfizer Offloads Its Last 7% Stake In Consumer Health Haleon For Over $3 Billion ↗

March 19, 2025

Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's largest shareholder with over 5%.

Via Benzinga

Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides ↗

March 19, 2025

HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the...

Via Benzinga

Topics Government

Peering Into GSK's Recent Short Interest ↗

February 24, 2025

Via Benzinga

Bear Of The Day: Gsk Plc ↗

February 06, 2025

GSK PLC is a Zacks Rank #5 (Strong Sell) after the company beat the Zacks Consensus Estimate when the last reported.

Via Talk Markets

Topics Stocks / Equities

GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study ↗

March 12, 2025

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early data on VH184 and VH499 therapies.

Via Benzinga

Why Moderna Stock Has Surged 20% This Week Despite Mixed News ↗

March 07, 2025

Recent news has been mixed with a patent win and loss in Germany and the U.S. But Moderna stock has risen markedly this week.

Via Investor's Business Daily

Topics Intellectual Property

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251 ↗

March 06, 2025

Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone adds $14M to cash reserves.

Via Benzinga

Topics Earnings

GSK's Once-Daily Inhalers For Smoker's Lung Has Potential Benefits: Independent Organization Report ↗

March 04, 2025

ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.

Via Benzinga

GSK's Twice-Yearly Depemokimab Reduces Nasal Polyp Size, Goes Under FDA Review ↗

March 03, 2025

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements.

Via Benzinga

Earnings Scheduled For February 5, 2025 ↗

February 05, 2025

Via Benzinga

Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis ↗

March 03, 2025

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

Via Benzinga

Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds ↗

February 27, 2025

Moderna is under pressure as two of its vaccines hit potential snags.

Via Investor's Business Daily

Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025 ↗

February 27, 2025

Haleon posted £11.23B in FY24 revenue, with 5% organic growth. 2025 guidance expects 4-6% organic growth, with profit gains weighted to the second half.

Via Benzinga

FDA Approves GSK's 5-in-1 Meningococcal Vaccine For Adolescents Ahead Of CDC Advisory Committee Vote Meeting Next Week ↗

February 18, 2025

GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage recommendations on Feb. 26.

Via Benzinga

Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors ↗

February 17, 2025

Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally.

Via Benzinga

Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty ↗

February 11, 2025

Goldman Sachs downgraded Dynavax to Sell, citing increased competition in the shingles vaccine market and uncertainty over hepatitis B revaccination demand.

Via Benzinga

Merck: 4 No-Brainer Reasons to Buy This Dip

February 10, 2025

Merck & Co. stock was pummeled by 10% after its earnings release on soft forecasts, but the overreaction by the market may present a buying opportunity.

Via MarketBeat

Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch ↗

February 10, 2025

A Nevada dairy worker who initially tested positive for bird flu is currently experiencing mild symptoms, including "pink eye."

Via Benzinga

Electronic Arts Posts Upbeat Earnings, Joins Mattel, Johnson Controls, Mueller Water Products And Other Big Stocks Moving Higher On Wednesday ↗

February 05, 2025

Via Benzinga

GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion ↗

February 05, 2025

GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company announced a $2.5 billion share buyback plan.

Via Benzinga

RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box. ↗

February 04, 2025

RFK Jr. cleared a key hurdle Tuesday after the Senate Finance Committee voted along party lines in favor of his nomination.

Via Investor's Business Daily

The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings ↗

January 29, 2025

The Senate will meet Wednesday to start the confirmation hearing process for Robert F. Kennedy Jr.

Via Investor's Business Daily

Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm? ↗

January 28, 2025

The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health Organization on Monday, marking a dramatic acceleration of President Donald...

Via Benzinga

Topics Government

Trump Administration Halts All Communications From The Centers For Disease Control As Bird Flu Spreads ↗

January 24, 2025

As the bird flu virus continues to spread through the United States, the Trump administration on Tuesday ordered all communications from the Centers for Disease Control and Prevention to stop.

Via Benzinga

Topics Government

After a Reset Year, Is Moderna Stock Poised for a Comeback?

January 22, 2025

Moderna had a rough 2024 and is starting 2025 with lowered forecasts, but is focused on getting 10 FDA approvals in the next three years. Is now time to buy?

Via MarketBeat

Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine ↗

January 21, 2025

According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of bird flu in the U.S. and one death associated with the virus.

Via Benzinga

Europe Drug Regulator Expands GSK's Jemperli/Chemo Combo To Adult Patients With Advanced Endometrial Cancer ↗

January 21, 2025

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant trial results.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.